Literature DB >> 19027731

Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats.

Jiangui He1, Yili Chen, Yiyi Huang, Fengjuan Yao, Zhongkai Wu, Shenglong Chen, Lichun Wang, Pingxi Xiao, Gang Dai, Rongsen Meng, Chengxi Zhang, Lilong Tang, Yuli Huang, Zhiming Li.   

Abstract

Although short-term B-type natriuretic peptide (BNP) treatment has been shown to be effective for decompensated congestive heart failure, little is known about the effects of long-term BNP treatment in ventricular remodeling and heart failure in response to myocardial infarction. The aim of the present study was to investigate the effects of long-term BNP treatment on ventricular remodeling and heart failure after myocardial infarction in rats. Myocardial infarction was induced by ligating the left anterior descending coronary artery. The surviving rats were randomly divided into four groups: 1) vehicle-treated myocardial infarction group ('vehicle-treated group'), 2) rats treated with low-dose BNP ('low BNP group'), 3) rats treated with high-dose BNP ('high BNP group'), 4) sham-operated group. Eight weeks after the operation, rats were sacrificed. Compared with the sham-operated group, the vehicle-treated group had significantly higher collagen deposition and angiotensin II levels (P<0.01) and a significantly lower cardiac function (P<0.05). Both BNP-treated groups had significant improvement of these indexes compared with the vehicle-treated group (P<0.01). The high BNP group had significantly less collagen deposition and better cardiac function than the untreated and low BNP groups. Moreover, the mRNA and protein expression of TGFbeta1 and Smad2 in the vehicle-treated group was significantly higher than in the sham-operated group (P<0.01). Both BNP-treated groups had a suppression of TGFbeta1 and Smad2 expression (P<0.01). In conclusion, long-term treatment with BNP prevents ventricular remodeling and deterioration of cardiac function in a dose-dependent fashion, a process that may be associated with the inhibition of TGFbeta1/ Smad2 signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027731     DOI: 10.1016/j.ejphar.2008.10.064

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Do engineered natriuretic peptides have greater therapeutic potential than do native peptides?

Authors:  Arthur H L From
Journal:  Cardiovasc Res       Date:  2010-10-08       Impact factor: 10.787

2.  Transforming growth factor β1 antagonizes the transcription, expression and vascular signaling of guanylyl cyclase/natriuretic peptide receptor A - role of δEF1.

Authors:  Anagha Sen; Prerna Kumar; Renu Garg; Sarah H Lindsey; Prasad V G Katakam; Meaghan Bloodworth; Kailash N Pandey
Journal:  FEBS J       Date:  2016-04-05       Impact factor: 5.542

Review 3.  Transforming growth factor β: A potential biomarker and therapeutic target of ventricular remodeling.

Authors:  Yuan Ma; Hai Zou; Xing-Xing Zhu; Jie Pang; Qiang Xu; Qin-Yang Jin; Ya-Hui Ding; Bing Zhou; Dong-Sheng Huang
Journal:  Oncotarget       Date:  2017-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.